Compugen Ltd. (NASDAQ:CGEN) Stock Has Average Target Price of $5.00 According to Analysts

Shares of Compugen Ltd. (NASDAQ:CGEN) have been assigned a consensus recommendation of “Buy” from the five ratings firms that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating on the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $5.00.

Several brokerages have recently commented on CGEN. Weiss Ratings upgraded Compugen from a “sell (d-)” rating to a “hold (c-)” rating in a research report on Wednesday, August 5th. HC Wainwright reiterated a “buy” rating on shares of Compugen in a research report on Tuesday, August 4th.

Compugen Price Performance

Shares of NASDAQ:CGEN opened at $2.38 on Wednesday. Compugen has a 1-year low of $1.37 and a 1-year high of $3.23. The company has a market capitalization of $225.03 million, a P/E ratio of 6.26 and a beta of 2.78. The firm’s 50 day simple moving average is $2.46 and its two-hundred day simple moving average is $2.43.

Compugen (NASDAQ:CGEN) last announced its quarterly earnings data on Monday, August 3rd. The biotechnology company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.01. The firm had revenue of $2.60 million for the quarter, compared to the consensus estimate of $1.28 million. Compugen had a net margin of 47.56% and a return on equity of 42.57%. During the same period last year, the firm earned ($0.08) EPS. On average, sell-side analysts anticipate that Compugen will post -0.28 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Compugen

Several institutional investors and hedge funds have recently modified their holdings of the stock. WINTON GROUP Ltd grew its stake in Compugen by 26.0% during the second quarter. WINTON GROUP Ltd now owns 197,110 shares of the biotechnology company’s stock valued at $422,000 after acquiring an additional 40,614 shares in the last quarter. Squarepoint Ops LLC bought a new position in shares of Compugen during the 2nd quarter valued at about $110,000. Glenmede Trust Co. NA boosted its holdings in shares of Compugen by 187.5% during the 1st quarter. Glenmede Trust Co. NA now owns 34,500 shares of the biotechnology company’s stock valued at $73,000 after purchasing an additional 22,500 shares during the last quarter. Renaissance Technologies LLC grew its position in shares of Compugen by 12.1% during the first quarter. Renaissance Technologies LLC now owns 1,632,988 shares of the biotechnology company’s stock valued at $3,478,000 after purchasing an additional 176,088 shares in the last quarter. Finally, Hillsdale Investment Management Inc. purchased a new position in shares of Compugen during the first quarter valued at about $68,000. Institutional investors own 12.22% of the company’s stock.

About Compugen

Compugen Ltd. is an Israeli clinical-stage biopharmaceutical company focused on discovering and developing therapeutics for cancer and other serious diseases. The company uses computational biology, data analysis and related technologies to identify novel drug targets and develop antibody-based medicines, with an emphasis on immuno-oncology.

Compugen’s pipeline includes investigational immune checkpoint therapies designed to reactivate anti-tumor immune responses. Its leading programs have included COM701, an antibody targeting PVRIG, and COM902, an antibody targeting TIGIT.